J Vet Sci. 2009 Mar;10(1):23-28
DOI: 10.4142/jvs.2009.10.1.23
  
 

Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells

Hyun Sun Cho1, Seung Hee Chang1,2, Youn Sun Chung1, Ji Young Shin1, Sung Jin Park1, Eun Sun Lee1, Soon Kyung Hwang1, Jung Taek Kwon1, Arash Minai Tehrani1, Minah Woo1, Mi Sook Noh1, Huda Hanifah1, Hua Jin1, Cheng Xiong Xu1, Myung Haing Cho1,2,*

 

1Laboratory of Toxicology, College of Veterinary Medicine, and 2Nano Systems Institute-National Core Research Center, Seoul National University, Seoul 151-742, Korea
* mchotox@snu.ac.kr

 

Tetrandrine (TET), a bis-benzylisoquinoline alkaloid from the root of Stephania tetrandra, is known to have anti-tumor activity in various malignant neoplasms. However, the precise mechanism by which TET inhibits tumor cell growth remains to be elucidated. The present studies were performed to characterize the potential effects of TET on phosphoinositide 3-kinase/Akt and extracellular signal-regulated kinase (ERK) pathways since these signaling pathways are known to be responsible for cell growth and survival. TET suppressed cell proliferation and induced apoptosis in A549 human lung carcinoma cells. TET treatment resulted in a down-regulation of Akt and ERK phosphorylation in both time-/concentrationdependent manners. The inhibition of ERK using PD98059 synergistically enhanced the TET-induced apoptosis of A549 cells whereas the inhibition of Akt using LY294002 had a less significant effect. Taken together, our results suggest that TET: i) selectively inhibits the proliferation of lung cancer cells by blocking Akt activation and ii) increases apoptosis by inhibiting ERK. The treatment of lung cancers with TET may enhance the efficacy of chemotherapy and radiotherapy and increase the apoptotic potential of lung cancer cells.